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The Doctor, The Patient, and The FDA
Herbert L. Ley, Jr.*
EDITOR'S NOTE: The four articles immediately following rep-
resent the Proceedings of the annual convocation of the Amer-
ican College of Legal Medicine, held in New York City in 1969.
Founded in 1960, this society has sought to bring together those
physicians and attorneys with a special interest, and/or exper-
tise, in the legal aspects of medicine. Further information on this
organization may be obtained from their main offices at 60 East
Scott Street, Chicago, Illinois. The Editors of the Cleveland
State Law Review are gratified that this periodical has been
honored by being designated as the vehicle for publication of the
papers of the ACLM Proceedings since shortly after the society
was organized. The four writers whose papers follow are typical
of the high calibre members of the American College of Legal
Medicine.
There have been considerable charges and counter-charges recently
about the United States Food and Drug Administration's role in pro-
tecting the consumer, at least as far as the medical profession is con-
cerned.
The FDA has absolutely no intention nor desire to assume the role
of the physician or to interfere with the bona fide practice of medicine.
The physician's primary concern is for the patient as stated in the Hip-
pocratic Oath which he subscribes to; and in Plato's statement about
physicians more than 2,000 years ago:
No physician, insofar as he is a physician, considers his own good
in what he prescribes, but the good of his patient; for the true physi-
cian is also a ruler having the human body as a subject, and is not
a mere money-maker.
The FDA and the physician possess in common a determination to pro-
tect the ultimate consumer, the patient. The FDA's purpose is spelled
out in the Food, Drug and Cosmetic Act;' and the FDA's actions to im-
plement it over the past half century have been upheld repeatedly and
consistently in the courts. The physician's purpose is evident in the
training, the dedication, and the single-minded devotion to what has been
described as "the only profession that labors incessantly to destroy the
reason for its own existence."
With so much in common, why then, the complaints by some persons
that the FDA's actions on drugs, including drug labelling, drug recalls
* Commissioner, U.S. Food and Drug Administration, in Washington, D.C.; M.D.,
Harvard Medical School, M.P.H., Harvard School of Public Health.
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and the withdrawal of certain drugs from the market, constitute at-
tempts to interfere with the practice of medicine? It is possible that one
of the reasons, and perhaps the principal one, for this misunderstanding
is the FDA's failure to communicate adequately its responsibility under
the law to protect the patient and inform the doctor.
It is vitally important for the physician to have the most accurate
and up-to-date information on drugs at all times. Similarly, it is the
FDA's duty to see to it that this kind of information is available to the
physician, promptly and without the distortions and exaggerations that
so often appear in drug advertising and promotion.
The FDA's authority to do this is clearly provided for in section 705
(b) of the FDC Act.2 It states in part:
The Secretary may also cause to be disseminated information re-
garding food, drugs, devices, or cosmetics, in situations involving,
in the opinion of the Secretary, imminent danger to health, or gross
deception of the consumer.
Significantly, the FDA has been upheld by the courts in several
cases in the last ten years in which this authority was challenged. In
the Hoxsey Cancer case 3 the FDA issued public warnings in 1956 and
1957 against the quack Hoxsey Cancer Treatment. Mr. Hoxsey filed suit
calling for the withdrawal of the warning which had been displayed in
Post Offices throughout the country. The Federal Judge in Washington
dismissed the case on a finding that section 705 (b) was constitutional
even though it does not provide for a public hearing before the warning
is issued. Again in 1964 a District Court Judge in Illinois said the FDA
was authorized to issue publicity concerning its investigation of a cancer
drug. And in 1967 a District Judge in Connecticut commended the FDA
for its publicity concerning a seizure of an electronic device. The judge
noted that Congress had imposed a duty upon the FDA to inform the
public against the use of certain treatments.
The FDA has issued "Dear Doctor" letters and has required drug
firms to issue such letters; and it has required changes in drug labelling
along with corrections by drug firms in their advertising and promotion
campaigns. It has issued newspaper releases, written magazine articles,
and its staff has appeared on television and radio in an effort to carry
through its basic responsibility to keep the public informed of the possible
health hazards and to keep the medical profession informed of drug
developments.
In my own testimony, I made clear the FDA's determination to ex-
ercise its responsibility in protecting the consumer. I stated:
When safety is not an issue, we do not plan to remove a drug from
distribution until the hearing is completed. But in those cases, we
2 52 Statute 1058 Sec. 705(b), 21 U.S.CA. 375(b).
3 Hoxsey Cancer Clinic v. Folsom, 155 F. Supp. 376 (D.C., D.C., 1957).
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will insist that the companies include in all promotional material an
affirmative disclosure of the Academic findings, and FDA's agree-
ment that the product is ineffective. This information is essential to
provide physicians with information that is highly relevant about
the drugs they prescribe for their patients.4
This referred to the National Academy of Sciences/National Research
Council findings on approximately 3,000 drugs marketed after 1962. The
Kefauver-Harris Amendments 5 to the Food, Drug and Cosmetic Act re-
quired that all drugs be effective, as well as safe.
Thus, in requiring drug companies to print the National Academy of
Sciences judgments on those drugs which the NAS/NRC finds are in-
effective, the FDA is following the Congressional mandate expressed
seven years ago. In those seven years, the drug companies have had more
than adequate opportunity to develop and present the kind of substantial
evidence that is needed to show that the drugs are, indeed, effective for
the diseases for which they are prescribed. Evidence is lacking in the
case of almost every drug which the NAS has found to be ineffective.
The FDA thinks that the physician wants to know which drugs
have been found ineffective and which present safety hazards. There are
differences among physicians as well as drug companies concerning the
NAS reports. The essential question is whether doctors should be in-
formed by a responsible, objective government agency of drug findings
by the top medical and scientific experts in the nation. The conclusion
is that the FDA does have that responsibility under the law, and that
physicians do want to receive that information.
With respect to curbing misleading and inaccurate drug advertising,
FDA regulations state clearly and unequivocally that advertising aimed
at physicians, and other health professionals, must be truthful, fairly
balanced, and informative.0 Also, the FDA has published new Federal
Regulations governing prescription drug advertising which became effec-
tive on June 16, 1969. 7 The Regulations require that representations re-
lating to the effectiveness of a drug must be balanced with information
on side effects and contra-indications.8 The claims of usefulness for a
drug may not exceed those permitted in the labelling approved by FDA.
The Regulations also list twenty specific practices which would make a
drug advertisement false and misleading, in violation of the law.9 Among
the prohibitions are any suggestions that the drug is better, more effec-
tive, useful in a broader range of patients, safer, or has fewer or less
4 Statement made before the Intergovernmental Relations Subcommittee of the
House Committee on Governmental Operations on May 13, 1969.
5 Drug Amendments of 1962, Public Law 87-781.
6 21 C.F.R. 1.105.
7 21 C.F.R. 1.105(e), Federal Food, Drug, and Cosmetic Act Sec. 502(n).
8 Ibid.
9 Id.
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serious side effects or limitations than can be supported by clinical ex-
perience or other substantial and objective evidence.
An example of possible misleading advertisement in Modern Medi-
cine concerned the drug Macrodantin, used for treatment of certain
infections of the genito-urinary tract. The FDA asked the drug company
to call the attention of all physicians in a letter to them, to certain mis-
leading claims in the ad. The question remains, however, as to how many
doctors actually read the letter.
The FDA took similar action against another drug company with re-
gard to an advertisement for Ismelin. Again, the drug company notified
all physicians of the portion of the ad which was regarded as misleading.
Again, how many physicians read that letter?
Many of the complaints about faulty medical advertising come from
physicians themselves; as well as from competing companies. In other
words, the doctors themselves realize that they need accurate informa-
tion on drugs, to provide the best possible patient care. They are upset
when a drug company or drug detail man tries to deceive them about
a product they might prescribe for one of their patients.
Unfortunately, communication is not a precise science. It is not like
chemistry, where you can predict with considerable accuracy the reac-
tions you will get when you mix two chemicals in a test tube. When the
FDA sends out a "Dear Doctor" letter, or issues a press release, or
makes a speech, it hopes to get a reaction. Rarely however, does it know
with any degree of accuracy how much of a reaction or whether the
reaction will prove to be the one anticipated.
The response to stimulus is what the communicators like to call
"feedback." They base the effect of their public relations or communi-
cations program on the amount of feedback they get, sometimes in terms
of letters or telephone calls, or hopefully in terms of some overt action
in the form of a resolution by the target of the particular communications
tool. This is the reason why the FDA is using every possible communi-
cations media to get their message through, in hope that one or two of
them, or perhaps more, will elicit feedback. They are meeting with the
editors of medical journals, including those published by the American
College of Physicians and the American Society of Internal Medicine.
The New England Journal of Medicine has been most cooperative in this
matter, having published a recent white paper on drug efficacy.
The FDA has recently established, as part of the Education and In-
formation Program, the position of medical communicator. It is his re-
sponsibility to prepare, implement and modify where necessary, a com-
munications program with the medical profession through a variety of
methods; including white papers, magazine articles, seminars, television
and radio programs, etc. In short, anything which will transmit the infor-
mation from the Bureau of Medicine to the physician.
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The FDA has discussed unsuccessfully with AMA representatives
the desirability of having the AMA News present a better balance of
significant issues in the drug area. In our opinion the AMA News has
devoted considerable space to statements criticizing either the FDA, the
National Academy of Sciences, or both. An example of this is an inter-
esting letter from a physician.10 He criticizes the FDA for proposing to
remove certain fixed antibiotic combinations from the market. The phy-
sician ends his letter this way:
Surely, all wisdom does not emanate from the Food and Drug Ad-
ministration, or the National Academy of Sciences.
The FDA would be first to agree with this writer, and nevertheless main-
tains its responsibility and duty to communicate its findings and those
of its experts and advisors to physicians, so that they can have the infor-
mation they need to use in the practice of medicine. An excellent answer
to that type of cricitism can also be found in the FDA's response to a
request from the AMA staff to a statement concerning a particular anti-
biotic (Panalba).
As physicians, we are concerned-all of us, with life itself, with the
protection of life and with the quality of life. To accomplish our side
of this awesome responsibility, we need your (physicians') co-
operation, your help, your understanding, your criticism, to guide us
in carrying on our functions.
In sum, the FDA can continue to make sure that the American drug
supply remains the safest and most effective in the world, and that the
FDA can share with the medical profession the best information we have
available on these drugs.
10 Letter appearing in the American Medical Association News, June 23, 1969.
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